RESUMEN
Monoclonal antibodies can provide important pre- or post-exposure protection against infectious disease for those not yet vaccinated or in individuals that fail to mount a protective immune response after vaccination. Inmazeb (REGN-EB3), a three-antibody cocktail against Ebola virus, lessened disease and improved survival in a controlled trial. Here, we present the cryo-EM structure at 3.1 Å of the Ebola virus glycoprotein, determined without symmetry averaging, in a simultaneous complex with the antibodies in the Inmazeb cocktail. This structure allows the modeling of previously disordered portions of the glycoprotein glycan cap, maps the non-overlapping epitopes of Inmazeb, and illuminates the basis for complementary activities and residues critical for resistance to escape by these and other clinically relevant antibodies. We further provide direct evidence that Inmazeb protects against the rapid emergence of escape mutants, whereas monotherapies even against conserved epitopes do not, supporting the benefit of a cocktail versus a monotherapy approach.
Asunto(s)
Ebolavirus , Fiebre Hemorrágica Ebola , Humanos , Anticuerpos Antivirales , Glicoproteínas , Epítopos , Anticuerpos NeutralizantesRESUMEN
Within this work, we present the first true three-dimensional (3D) analysis of chondrule size. Knowledge about the physical properties of chondrules is important for validating astrophysical theories concerning chondrule formation and their aggregation into the chondritic meteorites (known as chondrites) that contain them. The classification of chondrites into chemical groups also relies on chondrule properties, including their dimensions. Within this work, we quantify the diameters of chondrules in five ordinary chondrites (OCs; comprised of the H, L, and LL chondrites) and one low-iron enstatite (EL) chondrite. To extract the chondrule size data, we use x-ray computed microtomography to image small (~1-2 cm3 ) chondrite samples followed by manual digital segmentation to isolate chondrules within the volumes or subvolumes. Our data yield true 3D results without stereographic corrections necessary for two-dimensional (2D) or petrographic thin section-based determinations of chondrule sizes. Our results are completely novel, but are consistent with previous surface analysis (2D) data for OCs. Within our OC chondrule diameter data, we find the trend of mean chondrule diameters increasing in the order H < L < LL. We also present the first detailed EL chondrite chondrule size-frequency distribution. Finally, we examine the shapes and collective orientations of the chondrules within the chondrites and show that chondrite petrofabrics can be explored with our methodology. Chondrule shape-preferred orientations are identical to the orientations of the metal and sulfide grains in the chondrites and this is likely due to impact-related compaction. HIGHLIGHTS: We present a first true three-dimensional analysis of chondrule size. Our ordinary chondrite chondrule diameter data demonstrate the trend of mean chondrule diameters increasing in the order H chondrites < L chondrites < LL chondrites. We also present the first detailed low-iron enstatite chondrite chondrule size-frequency distribution. We examine the shapes and collective orientations of the chondrules and show that chondrite petrofabrics can be explored with our methodology.
RESUMEN
Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the combination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2 variants of concern/interest and also protects against emergence of new variants and their potential seeding into the population in a clinical setting.
Asunto(s)
Anticuerpos Monoclonales/inmunología , COVID-19/inmunología , COVID-19/prevención & control , Mutación/genética , SARS-CoV-2/genética , SARS-CoV-2/inmunología , Animales , COVID-19/virología , Chlorocebus aethiops , Cricetinae , Microscopía por Crioelectrón , Hospitalización , Humanos , Pulmón/patología , Pulmón/virología , Masculino , Pruebas de Neutralización , Células Vero , Carga ViralRESUMEN
Neutralizing antibodies have become an important tool in treating infectious diseases. Recently, two separate approaches yielded successful antibody treatments for Ebola-one from genetically humanized mice and the other from a human survivor. Here, we describe parallel efforts using both humanized mice and convalescent patients to generate antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, which yielded a large collection of fully human antibodies that were characterized for binding, neutralization, and three-dimensional structure. On the basis of these criteria, we selected pairs of highly potent individual antibodies that simultaneously bind the receptor binding domain of the spike protein, thereby providing ideal partners for a therapeutic antibody cocktail that aims to decrease the potential for virus escape mutants that might arise in response to selective pressure from a single-antibody treatment.
Asunto(s)
Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Betacoronavirus/inmunología , Infecciones por Coronavirus/inmunología , Neumonía Viral/inmunología , Glicoproteína de la Espiga del Coronavirus/inmunología , Adolescente , Adulto , Enzima Convertidora de Angiotensina 2 , Animales , Anticuerpos Neutralizantes/química , Anticuerpos Antivirales/química , Afinidad de Anticuerpos , Citotoxicidad Celular Dependiente de Anticuerpos , Betacoronavirus/química , Sitios de Unión de Anticuerpos , Anticuerpos ampliamente neutralizantes/química , Anticuerpos ampliamente neutralizantes/inmunología , COVID-19 , Línea Celular , Infecciones por Coronavirus/terapia , Citofagocitosis , Epítopos , Humanos , Inmunización Pasiva , Ratones , Persona de Mediana Edad , Modelos Moleculares , Pruebas de Neutralización , Pandemias , Peptidil-Dipeptidasa A/metabolismo , Dominios y Motivos de Interacción de Proteínas , Receptores de Coronavirus , Receptores Virales/metabolismo , Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo/inmunología , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/metabolismo , Adulto Joven , Sueroterapia para COVID-19RESUMEN
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.
Asunto(s)
Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Betacoronavirus/inmunología , Infecciones por Coronavirus/inmunología , Neumonía Viral/inmunología , Glicoproteína de la Espiga del Coronavirus/inmunología , Betacoronavirus/química , Betacoronavirus/genética , COVID-19 , Epítopos , Genoma Viral , Humanos , Proteínas Mutantes/química , Proteínas Mutantes/inmunología , Mutación , Pruebas de Neutralización , Pandemias , Dominios y Motivos de Interacción de Proteínas , SARS-CoV-2 , Selección Genética , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/genéticaRESUMEN
Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disorder caused by repetitive trauma to the central nervous system (CNS) suffered by soldiers, contact sport athletes, and civilians following accident-related trauma. CTE is a CNS tauopathy, with trauma-induced inflammation leading to accumulation of hyperphosphorylated forms of the microtubule-binding protein Tau (pTau), resulting in neurofibrillary tangles and progressive loss of neurons. At present, there are no therapies to treat CTE. We hypothesized that direct CNS administration of an adeno-associated virus (AAV) vector coding for an anti-pTau antibody would generate sufficient levels of anti-pTau in the CNS to suppress pTau accumulation thus interrupting the pathogenic process. Using a serotype AAVrh.10 gene transfer vector coding for a monoclonal antibody directed against pTau, we demonstrate the feasibility of this strategy in a murine CTE model in which pTau accumulation was elicited by repeated traumatic brain injury (TBI) using a closed cortical impact procedure over 5 days. Direct delivery of AAVrh.10 expression vectors coding for either of the two different anti-pTau antibodies to the hippocampus of these TBI mice significantly reduced pTau levels across the CNS. Using doses that can be safely scaled to humans, the data demonstrate that CNS administration of AAVrh.10anti-pTau is effective, providing a new strategy to interrupt the CTE consequences of TBI.